Additionally, in a xenograft model of HCC, the coadministration of the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with FGFR4-selective inhibitors facilitated tumor regression, which indicates a potential new strategy for HCC treatment [103]. Here, FGFR4 is linked to neoplasm.